Johnson & Johnson has unveiled new data from its Phase 1b/2 OrigAMI-4 study, demonstrating that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj combined with a PD-1 inhibitor produced clinically meaningful and durable antitumor activity in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The findings were presented during a plenary session at the 2026 Multidisciplinary Head and Neck Cancers Symposium.
The study focused on patients whose tumors were PD-L1-positive and unrelated to human papillomavirus (HPV), a subgroup that often faces particularly poor outcomes. Head and neck squamous cell carcinoma is widely recognized as an aggressive malignancy, and many patients experience disease recurrence or metastasis following their initial diagnosis. In the first-line recurrent or metastatic setting, current standards of care offer limited benefit. PD-1 inhibitor monotherapy has historically achieved response rates of approximately 18 percent, and adding chemotherapy has yielded only modest improvements.
These sobering outcomes have highlighted the urgent need for new therapeutic strategies that address additional biological drivers of disease. Researchers have increasingly focused on epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET) pathways, both of which are known to contribute to tumor growth and resistance to treatment. Evidence from lung cancer studies suggests that dual targeting of these pathways can alter disease biology and potentially improve patient outcomes.
According to investigators, the combination of subcutaneous amivantamab and immunotherapy may offer a more comprehensive approach by simultaneously targeting key mechanisms of tumor progression while harnessing the immune system. Ranee Mehra, M.D., Director of Head and Neck Medical Oncology and Professor of Medicine at the Marlene and Stewart Greenebaum Comprehensive Cancer Center at the University of Maryland, said that achieving rapid and durable disease control remains a primary objective in first-line treatment of head and neck cancer. She noted that combining subcutaneous amivantamab with immunotherapy appears promising because it targets central drivers of tumor growth and resistance, leading to deeper responses compared with current standards.
While the results are early-stage, the company emphasized that continued research will be essential to further define the therapy’s potential role in first-line treatment. If subsequent trials confirm these findings, the regimen could represent a significant advance for patients with PD-L1-positive, HPV-unrelated HNSCC, a population with limited effective treatment options and substantial unmet medical need.